<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02281214</url>
  </required_header>
  <id_info>
    <org_study_id>2014-A01163-44</org_study_id>
    <nct_id>NCT02281214</nct_id>
  </id_info>
  <brief_title>NGS Genome Analysis in Personalisation of Lung Cancer Treatment</brief_title>
  <acronym>ALCAPONE</acronym>
  <official_title>Genome Analysis by Next Generation Sequencing in Personalisation of Lung Cancer Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Georges Francois Leclerc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Georges Francois Leclerc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The identification of driver mutations in the epidermal growth factor receptor (EGFR) as the
      primary oncogenic event in a subset of lung adenocarcinomas led to a model of targeted
      treatment and genetic profiling of the disease. EGFR tyrosine kinase inhibitors (TKIs) confer
      remission in some patients, but use of the EGFR-TKIs is limited to patients with
      adenocarcinomas who have known activating EGFR mutations. And resistance to TKI treatment has
      become an increasingly important cause of treatment failure. Therefore, identification of the
      molecular components involved could lead to the development of effective therapy. Today only
      a limited number of genetic alterations are studied.

      Next Generation Sequencing (NGS) has the potential of becoming an important tool in clinical
      and therapeutic decision-making in oncology owing to its enhanced sensitivity in DND mutation
      detection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 24, 2014</start_date>
  <completion_date type="Actual">November 17, 2018</completion_date>
  <primary_completion_date type="Actual">November 17, 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>search for EGFR, KRAS, BRAF, PIK3CA, HER2, ERBB2, AKT1... mutations and ALK, ROS rearrangements by NGS</measure>
    <time_frame>search for EGFR, KRAS, BRAF, PIK3CA, HER2, ERBB2, AKT1,... mutations and ALK , ROS rearrangements by NGS methods before treatment and when tumor progression in patients with first line metastatic lung cancer therapy (chimiotherapy, targeted therapy)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>comparison of genome profiles (mutations and rearrangements)</measure>
    <time_frame>comparison of genome profiles (EGFR, KRAS, BRAF, PIK3CA, HER2, ERBB2, AKT1, ...mutations and ALK , ROS rearrangements) between targeted therapy for EGFR mutation and chemotherapy for non EGFR mutation</time_frame>
    <description>To compare gene profiles (EGFR, KRAS, BRAF, PIK3CA, HER2, ERBB2, AKT1, APC, ... mutations and ALK , ROS rearrangements) in primary lung tumors before treatment and when tumor progression on therapy according to treatment groups (targeted therapy for EGFR mutation and chemotherapy for non EGFR mutation) using NGS methods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tumor genetic profile (EGFR, KRAS, BRAF, PIK3CA, HER2, ERBB2, AKT1, APC, ... mutations and ALK , ROS rearrangements) and circulating DNA genetic profile (EGFR, KRAS, BRAF, PIK3CA, HER2, ERBB2, AKT1, APC, ... mutations and ALK , ROS rearrangements)</measure>
    <time_frame>To compare tumor genetic profile (EGFR, KRAS, BRAF, PIK3CA, HER2, ERBB2, AKT1, APC, ... mutations and ALK , ROS rearrangements) with circulating DNA genetic profile (EGFR, KRAS, BRAF, PIK3CA, HER2, ERBB2, ...mutations and rearrangements using NGS methods</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">165</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>blood sample, biopsy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood sample, biopsy</intervention_name>
    <description>Blood samples and tumor biopsies will taken from patients before treatment and when tumor progression on therapy for Next Generation Sequencing (NGS) mutation analysis</description>
    <arm_group_label>blood sample, biopsy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients of bronchial adénocarcinoma with metastases can benefit from first-line
             therapy - targeted therapy by tyrosine kinase inhibitor(TKI) for EGFR mutation and
             chemotherapy for non EGFR mutation)

          -  Patients with epidermoid cancer of the lungs can benefit from chemotherapy

          -  man and women

          -  age ≥ 18 years

          -  Patients have signed a written informed consent form

          -  Patients are affiliated to s social health insurance

        Exclusion Criteria:

          -  Survival time ≤ 3 months

          -  Patients with cerebral metastases

          -  Patients could not benefit from treatment for others diseases

          -  Pregnancy or breast-feeding

          -  Incapacity to sign the consent form for psychiatric, behavioural disorders

          -  Private individuals of freedom or under tutelage
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno COUDERT, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Georges François Leclerc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>October 23, 2014</study_first_submitted>
  <study_first_submitted_qc>October 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2014</study_first_posted>
  <last_update_submitted>January 2, 2019</last_update_submitted>
  <last_update_submitted_qc>January 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lung cancer, mutations</keyword>
  <keyword>patients</keyword>
  <keyword>mutations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

